nach oben

Erschienen in:

21.02.2017 | Original Research

DNMT3B −579 G>T Promoter Polymorphism and the Risk of Gastric Cancer in the West of Iran

verfasst von: Kulsom Ahmadi, Azam Soleimani, Shiva Irani, Aliasghar Kiani, Kourosh Ghanadi, Zahra Noormohamadi, Foroozan Sakinejad

Erschienen in: Journal of Gastrointestinal Cancer | Ausgabe 2/2018

Einloggen, um Zugang zu erhalten

Abstract

Background

Many studies have suggested that modulation of DNMT3B function caused by single nucleotide polymorphisms of the DNMT3B promoter region may underlie the susceptibility to various cancers such as tumors of the digestive system. The aim of this study was to investigate the effect of −579 G>T polymorphism in the promoter of the DNMT3B gene on risk of gastric cancer in a population from West Iran.

Patients and Methods

We conducted a case-control study in 100 gastric cancer patients and 112 cancer-free controls to assess the correlation between DNMT3B −579 G>T (rs1569686) polymorphism and the risk of gastric cancer. Detection of genotypes of DNMT3B G39179T polymorphism was analyzed by PCR-RFLP.

Results

There was no significant difference in the distribution of DNMT3B −579 G>T genotypes between the cases and controls. However, in the stratified analysis by clinicopathological characteristic types, we found that statistically, the risk susceptibility to gastric cancer was significantly associated with tumor grade II and GT/TT genotype of patients, compared to patients having GG genotype, (OR = 5.4737, 95% CI = 1.4746. 20.3184, P = 0.01).

Conclusions

Our study suggested that the −579 T allele may increase the relative risk for the progression of clinicopathological characteristic of tumor grade of gastric cancer patients.

Organization WH. Prioritizing a preventable epidemic: a primer for the media of noncommunicable diseases. 2011.

Babaei M, Mousavi S, Malek M, Tosi G, Masoumeh Z, Danaei N, et al. Cancer occurrence in Semnan Province, Iran: results of a population-based cancer registry. Asian Pac J Cancer Prev. 2005;6(2):159–64.PubMed

Sadjadi A, Malekzadeh R, Derakhshan MH, Sepehr A, Nouraie M, Sotoudeh M, et al. Cancer occurrence in Ardabil: results of a population-based cancer registry from Iran. Int J of Can. 2003;107(1):113–8.CrossRef

Yazdizadeh B, Jarrahi AM, Mortazavi H, Mohagheghi MA, Tahmasebi S, Nahvijo A. Time trends in the occurrence of major GI cancers in Iran. Asian Pac J Cancer Prev. 2005;6(2):130–4.PubMed

Berdasco M, Esteller M. Aberrant epigenetic landscape in cancer: how cellular identity goes awry. Dev Cell. 2010;19(5):698–711.CrossRefPubMed

Jones PA, Baylin SB. The epigenomics of cancer. Cell. 2007;128(4):683–92.CrossRefPubMedPubMedCentral

Li E, Zhang Y. DNA methylation in mammals. Cold Spring Harb Perspect Biol. 2014;6:a019133 1.CrossRef

He M, Fan J, Jiang R, Tang WX, Wang ZW. Expression of DNMTs and genomic DNA methylation in gastric signet ring cell carcinoma. Mol Med Rep. 2013;8(3):942–8.CrossRefPubMed

Chuang LS-H, Ian H-I, Koh T-W, Ng H-H, Xu G, Li BF. Human DNA-(cytosine-5) methyltransferase-PCNA complex as a target for p21WAF1. Science. 1997;277(5334):1996–2000.CrossRefPubMed

10.

Videtic Paska A, Hudler P. Aberrant methylation patterns in cancer: a clinical view. Biochemia medica. 2015;25(2):161–76.CrossRef

11.

Cao X-Y, Ma H-X, Shang Y-H, Jin M-S, Kong F, Jia Z-F, et al. DNA methyltransferase3a expression is an independent poor prognostic indicator in gastric cancer. World J Gastroenterol. 2014;20(25):8201–8.CrossRefPubMedPubMedCentral

12.

Oh B-K, Kim H, Park H-J, Shim Y-H, Choi J, Park C, et al. DNA methyltransferase expression and DNA methylation in human hepatocellular carcinoma and their clinicopathological correlation. In jJ of M M. 2007;20(1):65–74.

13.

Roll JD, Rivenbark AG, Jones WD, Coleman WB. DNMT3b overexpression contributes to a hypermethylator phenotype in human breast cancer cell lines. Mol Can. 2008;7(1):1.

14.

Zhang W, Xu J. DNA methyltransferases and their roles in tumorigenesis. Bio Res. 2017;5(1):1.

15.

Neves M, Ribeiro J, Medeiros R, Sousa H. Genetic polymorphism in DNMTs and gastric cancer: a systematic review and meta-analysis. Porto Biomedical Journal. 2016;1(5):164–72.CrossRef

16.

Shen H, Wang L, Spitz MR, Hong WK, Mao L, Wei Q. A novel polymorphism in human cytosine DNA-methyltransferase-3B promoter is associated with an increased risk of lung cancer. Can Res. 2002;62(17):4992–5.

17.

Chang K-P, Hao S-P, Liu C-T, Cheng M-H, Chang Y-L, Lee Y-S, et al. Promoter polymorphisms of DNMT3B and the risk of head and neck squamous cell carcinoma in Taiwan: a case–control study. Oral Onc. 2007;43(4):345–51.CrossRef

18.

Fan H, Liu D-S, Zhang S-H, Hu J-B, Zhang F, Zhao Z-J. DNMT3B 579 G>T promoter polymorphism and risk of esophagus carcinoma in Chinese. World Jof Gas. 2008;14(14):2230.CrossRef

19.

Fan H, Zhang F, Hu J, Liu D, Zhao Z. Promoter polymorphisms of DNMT3B and the risk of colorectal cancer in Chinese: a case-control study. J of Expe & Clin Can Res. 2008;27(1):1.CrossRef

20.

Perfilyeva A, Abdikerim S, Zhunussova G, Iksan O, Skvortsova L. G39179T DNMT3B gene variants in relation to colorectal cancer risk in Kazakhstan population. J Carcinog Mutagene. 2015;6(242):2.

21.

Yanagisawa Y, Ito E, Yuasa Y, Maruyama K. The human DNA methyltransferases DNMT3A and DNMT3B have two types of promoters with different CpG contents. Biochimica Biophys Acta. 2002;1577(3):457–65.CrossRef

22.

Zhang Y, Xu H, Shen Y, Gong Z, Xiao T. Association of DNMT3B -283 T > C and -579 G > T polymorphisms with decreased cancer risk: evidence from a meta-analysis. Int J Clin Exp Med. 2015;15(8):13028–38.

23.

Hu B, El Hajj N, Sittler S, Lammert N, Barnes R, Meloni-Ehrig A. Gastric cancer: classification, histology and application of molecular pathology. J Gastrointest Oncol. 2012;3(3):251–61.PubMedPubMedCentral

24.

Yada T, Yokoi C, Uemura N. The current state of diagnosis and treatment for early gastric cancer. Diagn and The Endosc. 2013;2013:241320. doi:10.1155/2013/241320.

25.

Kanai Y, Hirohashi S. Alterations of DNA methylation associated with abnormalities of DNA methyltransferases in human cancers during transition from a precancerous to a malignant state. Carcinogenesis. 2007;28(12):2434–42.CrossRefPubMed

26.

Sadikovic B, Al-Romaih K, Squire J, Zielenska M. Cause and consequences of genetic and epigenetic alterations in human cancer. Current Geno. 2008;9(6):394–408.CrossRef

27.

Chang KP, Hao SP, Liu CT, Cheng MH, Chang YL, et al. Promoter polymorphisms of DNMT3B and the risk of head and neck squamous cell carcinoma in Taiwan: a case-control study. Oral Oncol. 2007;43:345–51.CrossRefPubMed

28.

Fan H, Liu DS, Zhang SH, Hu JB, Zhang F, et al. DNMT3B 579 G>T promoter polymorphism and risk of esophagus carcinoma in Chinese. World J Gastroenterol. 2008;14:2230–4.CrossRefPubMedPubMedCentral

29.

Hernández-Sotelo D, García-Aguilar R, Castro-Coronel Y, Jonathan JM, Leyva-Vazquez MA, et al. The 46359CT polymorphism of DNMT3B is associated with the risk of cervical cancer. Mol Biol Rep. 2013;40:4275–80.CrossRefPubMed

30.

Mostowska A, Sajdak S, Pawlik P, Lianeri M, Jagodzinski PP. DNMT1, DNMT3A and DNMT3B gene variants in relation to ovarian cancer risk in the Polish population. Mol Biol Rep. 2013;40:4893–9.CrossRefPubMedPubMedCentral

31.

Wang C, Jia Z, Cao D, You L, Jin M, Wu X, et al. Polymorphism of DNA methyltransferase 3b and association with development and prognosis in gastric cancer. PLoS One. 2015;10(8):e0134059.CrossRefPubMedPubMedCentral

32.

Zhu S, Zhang H, Tang Y, Liu P, Wang J. DNMT3B polymorphisms and cancer risk: a meta analysis of 24 case–control studies. Mole Bio Repo. 2012;39(4):4429–37.CrossRef

33.

Kanai Y. Alterations of DNA methylation and clinicopathological diversity of human cancers. Path Inte. 2008;58(9):544–58.CrossRef

34.

Etoh T, Kanai Y, Ushijima S, Nakagawa T, Nakanishi Y, Sasako M, et al. Increased DNA methyltransferase 1 (DNMT1) protein expression correlates significantly with poorer tumor differentiation and frequent DNA hypermethylation of multiple CpG islands in gastric cancers. Am J of Path. 2004;164(2):689–99.CrossRef

35.

Bin X. Il-6 2174g> c polymorphism and cancer risk: a meta-analysis involving 29,377 cases and 37,739 controls. Int J of Uro. 2012;19:197.

36.

Gilliland FD. Ethnic differences in cancer incidence: a marker for inherited susceptibility? Envi Heal Persp. 1997;105(Suppl 4):897.CrossRef

37.

Cheng L, Qiu L, Jia M, Zhou F, Wang M, Zhang R, et al. Is there a dose-dependent effect of genetic susceptibility loci for gastric cancer on prognosis of the patients? Oncotarget. 2016; doi:10.18632/oncotarget.13123.

38.

Henderson BE, Lee NH, Seewaldt V, Shen H. The influence of race and ethnicity on the biology of cancer. Nate Rev Can. 2012;12(9):648–53.CrossRef

39.

Wogan GN, Hecht SS, Felton JS, Conney AH, Loeb LA, editors. Environmental and chemical carcinogenesis. Seminars in Can Bio; 2004: Elsevier.

Titel: DNMT3B −579 G>T Promoter Polymorphism and the Risk of Gastric Cancer in the West of Iran
verfasst von: Kulsom Ahmadi
Azam Soleimani
Shiva Irani
Aliasghar Kiani
Kourosh Ghanadi
Zahra Noormohamadi
Foroozan Sakinejad
Publikationsdatum: 21.02.2017
Verlag: Springer US
Erschienen in: Journal of Gastrointestinal Cancer / Ausgabe 2/2018
Print ISSN: 1941-6628
Elektronische ISSN: 1941-6636
DOI: https://doi.org/10.1007/s12029-017-9928-7

Neu im Fachgebiet Onkologie

24.04.2024 | DGIM 2024 | Nachrichten

Springer Medizin

DNMT3B −579 G>T Promoter Polymorphism and the Risk of Gastric Cancer in the West of Iran

Abstract

Background

Patients and Methods

Results

Conclusions

Neu im Fachgebiet Onkologie

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Krebspatienten impfen: Was? Wen? Und wann nicht?

Müde im Alter? Auch an die Nebenniere denken

Update Onkologie

Springer Medizin

Abstract

Background

Patients and Methods

Results

Conclusions

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 2/2018

Surgico-pathological Outcomes of 148 Radical Cholecystectomies Using Systematic Regional Lymphadenectomy Protocol: a Retrospective Study

Comparison of Clinical Outcomes Between Laparoscopic-Assisted and Minilaparotomy Approaches for Colon Cancer

Molecular Profiling of Synchronous Colon Cancers and Anaplastic Thyroid Cancer in a Patient with Lynch Syndrome

Outcomes of a Phase I/II Trial of Hepatic Arterial Infusion of Oxaliplatin Combined with Intravenous 5-Fluorouracil and l-Leucovorin in Patients with Unresectable Liver Metastases from Colorectal Cancer After Systemic Chemotherapy Failure

Clinicopathological Associations of K-RAS and N-RAS Mutations in Indonesian Colorectal Cancer Cohort

Author Correction: Opium Consumption and the Incidence of Cancer: Does Opium Account as an Emerging Risk Factor for Gastrointestinal Cancer?

Neu im Fachgebiet Onkologie

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Krebspatienten impfen: Was? Wen? Und wann nicht?

Müde im Alter? Auch an die Nebenniere denken

Update Onkologie